OUR MISSION

About Us

The Focal Therapy Society aims to advance and position minimally invasive treatments and image-targeted cancer treatment in a safe and effective gland-preserving manner to extend and maintain one’s quality of life.

OUR VISION

To control or eradicate prostate and kidney cancer in a minimally invasive, image-targeted manner while optimizing the preservation of organ function.

ABOUT

Our History

The beginnings of the society can be traced back to 2008 when we met as an international workshop, or think-tank, of key opinion leaders determined to develop a means to treat localized prostate cancer in a minimally invasive manner while sparing the non-malignant portions of the prostate in an effort to preserve a man’s urinary continence and potency. Given this ambitious goal, we were very inclusive from the onset, understanding that for focal therapy to succeed, it will require a multi-disciplinary effort teaming-up urologists, radiation oncologists, medical oncologists, pathologists, radiologists, biomedical engineers, new discoveries in pharma along with the medical imaging and device industry. Ultimately the patient with need to get involved as this new platform of targeting, treating and managing prostate and kidney cancer was being developed with their interest in mind.

Since inception, the symposium has rotated between North America, Europe and Japan, occurring during the Spring of each year.

 

The Society and Symposium have a purely educational focus aimed at addressing key issues and latest developments in the minimally invasive treatment (focal therapy) that destroys the known area(s) of cancer.

The Symposium includes first class and forward thinking presentations by distinguished and pioneering faculty are selected to serve the educational goals, with video sessions being an important component of the program.In October 2019, the Focal Therapy Society was officially incorporated by joining with the Endourological Society. The Endourological Society is a non-profit organization founded in 1983 by a group of international urologists. The Focal Therapy Society’s founding executives are led by Thomas Polascik (Founding President), Jean De-La- Rosette, Rafael Sanchez-Salas and Ardeshir Rastinehad.

ABOUT

Society Members

Thomas Polascik
PRESIDENT
USA
Jean de la Rosette
VICE PRESIDENT
TURKEY
Rafael Sanchez Salas
SECRETARY
FRANCE
Art Rastinehad
SECRETARY ELECT
USA

Jonathan Coleman

USA

Inderbir Gill

USA

Georg Salomon

GERMANY

Sebastian Crouzet

FRANCE

Laurence Klotz

CANADA

Jack Tay

SINGAPORE

Mark Emberton

ENGLAND

Pilar Laguna

TURKEY

Samir Taneja

USA

John Feller

USA

Herbert Lepor

USA

Massimo Valerio

SWITZERLAND

Antonio Finelli

CANADA

Osamu Okimura

JAPAN

Jochen Walz

FRANCE

Jürgen Futterer

NETHERLANDS

Peter Pinto

USA

John Ward

USA

Arvin George

USA

Cary Robertson

USA

Jeffrey Cadeddu

USA

Thomas Polascik
PRESIDENT
USA
Jean de la Rosette
VICE PRESIDENT
TURKEY
Rafael Sanchez Salas
SECRETARY
FRANCE
Art Rastinehad
SCIENTIFIC CHAIR
USA
ABOUT

In Memoriam

Please consider supporting Vladimir Mouraviev’s family and help ease at least their financial burden. All donations regardless of size will help.

DONATE TODAY  →

May his memory, passion and founding efforts in Focal Therapy, endure.

 

Vladimir Mouraviev MD PhD joined the Duke Urology research group as a Research Fellow in the Summer of 2005. He began working on Focal Therapy as a potential new treatment for localized prostate cancer that promised to be a paradigm shift away from traditional whole-gland treatment. Little did he know at the time the impact and legacy this will eventually have on targeted treatment of prostate cancer.

Academically, Vladimir was an extremely capable, gifted scientist and clinician. During his 5+-year tenure at Duke, he was the most dedicated and hardest working individual I had known.

ABOUT

Gallery

Relive moments from our past symposiums and some of our other great gatherings.